文献速递多重用药老年慢病共病管理

选择性5-羟色胺再摄取抑制剂与抗血栓药联用的大出血风险:全国病例-病例-时间-对照研究

Risk of major bleeding events associated with concomitant use of selective serotonin reuptake inhibitors and anti-thrombotic drugs: a nationwide case-case-time-control study.
PubMed 文献 · Age Ageing · 2026-01-01

该研究采用病例-病例-时间-对照设计,纳入同时使用选择性5-羟色胺再摄取抑制剂(SSRI)和抗血栓药后新诊断大出血的患者,按年龄、性别和队列进入日期匹配未来尚未出血的病例。在SSRI联合抗凝药使用者中(110 540例,平均年龄67.7岁),校正暴露时间趋势后大出血风险未显著增加(aOR 1.07,95%CI 0.89-1.28);在SSRI联合抗血小板药使用者中(105 464例,平均年龄58.6岁),风险同样未显著增加(aOR 1.10,95%CI 0.88-1.38)。

要点

  • SSRI联合抗凝药未显著增加大出血风险(aOR 1.07,95%CI 0.89-1.28)。
  • SSRI联合抗血小板药未显著增加大出血风险(aOR 1.10,95%CI 0.88-1.38)。
  • 按性别和年龄分层亚组分析结果与主分析一致。

核心结论

  • 同时使用SSRI与抗血栓药未观察到重大出血风险显著增加。
  • 临床处方此类联合用药时仍应进行个体化风险-获益评估。

研究设计与样本

  • 全国性病例-病例-时间-对照研究。
  • 纳入同时处方SSRI和抗血栓药后新诊断大出血的个体,按年龄、性别和队列进入日期匹配未来尚未出血的病例。
  • 采用条件logistic回归估计校正比值比(aOR)及95%置信区间(CI)。

主要发现

  • SSRI联合抗凝药使用者中,110 540例匹配未来病例(平均年龄67.7岁;女性49.7%),大出血风险aOR 1.07(95%CI 0.89-1.28)。
  • SSRI联合抗血小板药使用者中,105 464例匹配(平均年龄58.6岁;女性48.6%),大出血风险aOR 1.10(95%CI 0.88-1.38)。
  • 按性别和年龄分层亚组分析结果与主分析一致。

临床怎么用

  • 老年医学科处方SSRI联合抗血栓药时,可参考本研究的风险估计进行个体化决策。
  • 对高龄、共病多、出血风险高的患者,仍需结合临床综合评估风险与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression is common in older adults, who are also at elevated risk of bleeding due to age-related physiological changes and comorbidities. Concerns have been raised regarding potential bleeding risk from concomitant use of selective serotonin reuptake inhibitors (SSRIs) and antithrombotic agents. OBJECTIVE: To assess whether the risk of major bleeding is associated with the concomitant use of SSRIs and antithrombotic agents. DESIGN: Case-case-time-control. METHOD: We included individuals prescribed both SSRIs and antithrombotics who were newly diagnosed with major bleeding. To adjust for exposure time trend, each patient who experienced a major bleeding was matched with future cases who had not yet experienced bleeding, by age, sex and cohort entry date. Conditional logistic regression was used to estimate adjusted odds ratio (aOR) and 95% confidence interval (CI) for risk period compared with five control periods. RESULTS: Among SSRIs and anticoagulant users, 110 540 were matched with future cases (mean age 67.7 years; 49.7% female). After accounting for the time-trends in exposure, concomitant use did not significantly increase the risk of major bleeding (aOR 1.07, 95% CI 0.89-1.28). Similarly, among SSRIs and antiplatelet users, 105 464 patients were matched (mean age 58.6 years; 48.6% female), and no significant increase in bleeding risk was observed (aOR 1.10, 95% CI 0.88-1.38). The subgroup analyses stratified by sex and age were consistent with the main results. CONCLUSION: No significant increase in the major bleeding risk was observed with concomitant use of SSRIs and antithrombotic agents. However, clinicians should consider individual risk-benefit assessments when prescribing these combinations.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Kim S, Kim JH, Shin JY, et al. Risk of major bleeding events associated with concomitant use of selective serotonin reuptake inhibitors and anti-thrombotic drugs: a nationwide case-case-time-control study. Age Ageing. 2026. PMID: 42149695. doi:10.1093/ageing/afag105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。